Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Mutation is the source of all heritable diversity, the essential material of evolution and breeding. While mutation rates are often regarded as constant, variability in mutation rates has been observed at nearly every level-varying across mutation types, genome locations, gene functions, epigenomic contexts, environmental conditions, genotypes, and species. This mutation rate variation arises from differential rates of DNA damage, repair, and transposable element activation and insertion that together produce what is measured by DNA mutation rates. We review historical and recent investigations into the causes and consequences of mutation rate variability in plants by focusing on the mechanisms shaping this variation. Emerging mechanistic models point to the evolvability of mutation rate variation across genomes via mechanisms that target DNA repair, shaping the diversification of plants at phenotypic and genomic scales.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1146/annurev-arplant-070522-054109 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
First-Line Aumolertinib in -Mutant Advanced Non-Small Cell Lung Cancer: A Multicenter Real-World Retrospective Study with a Four-Year Follow-Up.
Oncol Res
September 2025
Department of Oncology, Affiliated Hospital of Guilin Medical University, Guilin, 541001, China.
Background: The use of third-generation different tyrosine kinase inhibitors (TKIs) is considered the most effective option for treating advanced non-small cell lung cancer (aNSCLC) with epidermal growth factor receptor (EGFR) mutations. However, there is limited information on the efficacy and safety of aumolertinib in patients remains these cases.
Methods: The clinical records of patients receiving aumolertinib as first-line therapy across four hospitals in the Guangxi Zhuang Autonomous Region from April 2020 to December 2021 were retrospectively analyzed, using progression-free survival (PFS) as the primary endpoint and overall survival (OS) representing the secondary endpoint.
Comparative efficacy and safety of therapeutic strategies for EGFRvIII positive recurrent glioblastoma.
iScience
September 2025
Beijing Institute of Brain Disorders, Laboratory of Brain Disorders, Ministry of Science and Technology, Collaborative Innovation Center for Brain Disorders, Capital Medical University, No.10 Xitoutiao You'anmenwai Fengtai District, Beijing 100069, P.R. China.
Glioblastoma multiforme (GBM) is the most aggressive primary brain tumor, and EGFRvIII mutation has been associated with treatment resistance and poor prognosis, highlighting the need for more effective therapeutic strategies. We conducted a random-effects Bayesian network meta-analysis to compare the efficacy and safety of treatments for EGFRvIII-positive recurrent GBM (rGBM), evaluating overall survival (OS), progression-free survival (PFS), and objective response rate (ORR). Seven clinical trials were included ( = 716).
View Article and Find Full Text PDFPhenotype and genotype in hereditary chronic intestinal pseudo-obstruction with small intestine involvement.
Front Med (Lausanne)
August 2025
Department of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Chronic intestinal pseudo-obstruction (CIPO) is a rare and severe intestinal motility disorder with poor long-term prognosis and high mortality rate, especially when the small intestine is involved. Due to the non-specificity of clinical symptoms, CIPO has long faced diagnostic challenges. With the advancements of sequencing technology, many hereditary CIPOs have been identified.
View Article and Find Full Text PDFEnhancing diagnostic efficiency of pyrazinamide resistance in via modified MGIT assay and genotypic correlation.
Curr Res Microb Sci
August 2025
Department of Immunology, ICMR-National Institute for Research in Tuberculosis, Chennai, India.
Pyrazinamide (PZA) plays a crucial role in the treatment of both active and latent tuberculosis, particularly in regimens designed to treat drug-resistant TB. However, diagnosing resistance to PZA poses challenges for managing TB, highlighting the need for accurate detection methods. This study aims to address the challenges in detecting PZA resistance by modifying the standard MGIT960 PZA drug susceptibility testing method by optimizing the inoculum dilution.
View Article and Find Full Text PDFCYP2C19 Genetic Variants Associated with Clopidogrel Resistance and Major Adverse Cardiovascular Events in Vietnamese Patients Undergoing Percutaneous Coronary Intervention.
Cardiovasc Hematol Disord Drug Targets
August 2025
Institute of Pharmacy Training, Vietnam Military Medical University, Hanoi, Vietnam.
Introduction: Acute coronary syndrome (ACS) is a leading cause of death, and clopidogrel resistance remains a major challenge in its treatment. This study aims to determine the impact of CYP2C19 genetic variants on clopidogrel resistance (CR) and major adverse cardiovascular events (MACEs) in Vietnamese patients undergoing percutaneous coronary intervention (PCI).
Methods: We carried out a descriptive cross-sectional study, supplemented by a prospective longitudinal follow-up, on 113 ACS patients undergoing PCI with drug-eluting stent implantation at the Department of Cardiology, Military Hospital 103, from January 2015 to May 2018.